Magrath 1976.

Methods	Randomised, parallel group, single‐centre trial (Uganda). ITT: unclear. Withdrawals: stated.
Participants	Baseline characteristics: screening population: 80; 48 participants randomised (40 evaluated: BCG: 21; control: 19; male:female: BCG 15:6; control: 14:5). Mean age: BCG: 10 years; control: 6 years. Tumour staging: WHO classification. Diagnosis: histopathology. Entry criteria: untreated BL; remission two weeks after treatment with C.
Interventions	BCG versus no treatment. Participants randomised if in remission two weeks after the last dose of C. Follow‐up: median 1.75 years.
Outcomes	Relapse. Overall survival. Event‐free survival. Toxicity.
Notes	Participants recruited if in remission. Study type: remittance maintenance.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Said to be "randomised by stage".
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding (performance bias and detection bias) All outcomes	High risk	Unlikely: therapy involved scarification.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were accounted for.